scholarly journals The Clinical Efficacy and Safety of Four-Weekly Docetaxel as First-Line Therapy in Elderly Lung Cancer Patients with Squamous Cell Carcinoma

2019 ◽  
Vol 82 (3) ◽  
pp. 211
Author(s):  
Jong Hyun Choi ◽  
Juwhan Choi ◽  
Sang Mi Chung ◽  
Jee Youn Oh ◽  
Young Seok Lee ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Cancer Patients ◽  
Efficacy And Safety ◽  
First Line ◽  
Lung Cancer Patients ◽  
Weekly Docetaxel ◽  
First Line Therapy ◽  
Line Therapy

Outcome of Surgical Resection as a First Line Therapy in T3 Non-small Cell Lung Cancer Patients

2013 ◽  
Vol 37 (11) ◽  
pp. 2574-2580 ◽  
Author(s):  
Tomoyoshi Takenaka ◽  
Masakazu Katsura ◽  
Yasunori Shikada ◽  
Sadanori Takeo
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Surgical Resection ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Line ◽  
Lung Cancer Patients ◽  
First Line Therapy ◽  
Line Therapy

Exceptional Response to PD-1 Blockade as First-Line Therapy in Head and Neck Squamous Cell Carcinoma

ORL ◽  
2020 ◽  
Vol 82 (6) ◽  
pp. 343-350
Author(s):  
Takumi Kumai ◽  
Hiroki Komatsuda ◽  
Yoshinori Minami ◽  
Yasuaki Harabuchi
Keyword(s):  
Lung Cancer ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Maxillary Sinus ◽  
Squamous Cell ◽  
Neck Squamous Cell Carcinoma ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy

The effect of PD-1 blockade as a first-line therapy in nonmetastatic head and neck squamous cell carcinoma (HNSCC) remains unknown. We report a case of an exceptional response to PD-1 blockade as a first-line therapy in a patient with HNSCC and lung cancer. A 59-year-old man presented with cheek swelling and chest pain. He was diagnosed with maxillary sinus carcinoma (squamous cell carcinoma) and lung cancer (non-small-cell lung cancer, not otherwise specified). The maxillary sinus carcinoma was completely resolved after 8 cycles of pembrolizumab. Immune checkpoint blockade warrants further evaluation in previously untreated patients with HNSCC.

Checkpoints inhibitors in first line therapy of metastatic non-small cell lung cancer patients

2016 ◽  
Vol 5 (S7) ◽  
pp. S1443-S1448
Author(s):  
Luis E. Raez ◽  
Christian Rolfo ◽  
Mauricio Mahave ◽  
Christian Caglevic
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Line ◽  
Lung Cancer Patients ◽  
First Line Therapy ◽  
Line Therapy
Sign in / Sign up

Export Citation Format

Share Document